Patents by Inventor BYRON DELABARRE

BYRON DELABARRE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PURINES AND METHODS OF THEIR USE
    Publication number: 20240150358
    Abstract: Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.
    Type: Application
    Filed: June 3, 2021
    Publication date: May 9, 2024
    Inventors: Kerem OZBOYA, Iwona WRONA, Bertrand LE BOURDONNEC, Matthew LUCAS, Vanessa KURIA, Madeline MACDONNELL, Byron DELABARRE
  • Bi-Specific Fusion Proteins
    Publication number: 20240101713
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Application
    Filed: October 9, 2023
    Publication date: March 28, 2024
    Applicant: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-specific fusion proteins
    Patent number: 11814443
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: November 14, 2023
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • AMINO ALCOHOL COMPOUNDS AND USES THEREOF
    Publication number: 20230339890
    Abstract: The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.
    Type: Application
    Filed: June 3, 2021
    Publication date: October 26, 2023
    Inventors: Iwona WRONA, Kerem OZBOYA, Bertrand LE BOURDONNEC, Vanessa KURIA, Madeline MACDONNELL, Matthew LUCAS, Byron DELABARRE
  • Bi-Specific Fusion Proteins
    Publication number: 20230322951
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Application
    Filed: May 3, 2023
    Publication date: October 12, 2023
    Applicant: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • BICYCLIC HETEROARENES AND METHODS OF THEIR USE
    Publication number: 20230271965
    Abstract: Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.
    Type: Application
    Filed: June 3, 2021
    Publication date: August 31, 2023
    Inventors: Kerem OZBOYA, Iwona WRONA, Bertrand LE BOURDONNEC, Matthew LUCAS, Vanessa KURIA, Madeline MACDONNELL, Byron DELABARRE
  • THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
    Publication number: 20230250078
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Application
    Filed: September 9, 2022
    Publication date: August 10, 2023
    Inventors: Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
  • Bi-specific fusion proteins
    Patent number: 11673970
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: June 13, 2023
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • PDE5 compositions and methods for immunotherapy
    Patent number: 11666642
    Abstract: The present invention relates to compositions and methods for the regulated and controlled expression of proteins. Methods for inducing anti-cancer immune responses in a subject are also provided.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: June 6, 2023
    Assignee: OBSIDIAN THERAPEUTICS, INC.
    Inventors: Vipin Suri, Byron Delabarre, Michael N. Gladstone, Celeste Richardson, Brian Dolinski, Abhishek Kulkarni, Mara Christine Inniss, Dexue Sun, Dan Jun Li, Grace Y. Olinger, Scott Francis Heller
  • DHFR tunable protein regulation
    Patent number: 11629340
    Abstract: The present invention is related to compositions and methods for the regulated and controlled expression of proteins.
    Type: Grant
    Filed: September 2, 2019
    Date of Patent: April 18, 2023
    Assignee: OBSIDIAN THERAPEUTICS, INC.
    Inventors: Vipin Suri, Dan Jun Li, Dexue Sun, Byron Delabarre, Vijaya Balakrishnan, Brian Dolinski, Mara Christine Inniss, Grace Y. Olinger
  • PDE5 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
    Publication number: 20230074330
    Abstract: The present invention relates to compositions and methods for the regulated and controlled expression of proteins. Methods for inducing anti-cancer immune responses in a subject are also provided.
    Type: Application
    Filed: February 1, 2022
    Publication date: March 9, 2023
    Applicant: Obsidian Therapeutics, Inc.
    Inventors: Vipin Suri, Byron Delabarre, Michael N. Gladstone, Celeste Richardson, Brian Dolinski, Abhishek Kulkarni, Mara Christine Inniss, Dexue Sun, Dan Jun Li, Grace Y. Olinger, Scott Francis Heller
  • PDE5 DERIVED REGULATORY CONSTRUCTS AND METHODS OF USE IN IMMUNOTHERAPY
    Publication number: 20220403001
    Abstract: The present disclosure relates to tunable biocircuit systems for the development of controlled and/or regulated therapeutic systems. In particular, regulatable biocircuits containing destabilizing domains (DD) derived from mutant human cGMP-specific phosphodiesterase type 5 (PDE5) are disclosed. Especially, the present disclosure provides an effector module. Such effector module may include (a) a stimulus response element (SRE), wherein the SRE is a DD, said DD comprising at least one mutation relative to cGMP-specific 3?,5?-cyclic phosphodiesterase (hPDE5; SEQ ID NO: 1) and (b) at least one payload, which is attached, appended or associated with said SRE. The SRE may be responsive to one or more stimuli.
    Type: Application
    Filed: June 12, 2019
    Publication date: December 22, 2022
    Applicant: Obsidian Therapeutics, Inc.
    Inventors: Vipin SURI, Celeste RICHARDSON, Brian DOLINSKI, Abhishek KULKARNI, Mara Christine INNISS, Dexue SUN, Dan Jun LI, Grace Y. OLINGER, Scott Francis HELLER, Jennifer Leah GORI, Byron DELABARRE
  • Therapeutically active compounds and their methods of use
    Patent number: 11505538
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: November 22, 2022
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
  • THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
    Publication number: 20220348554
    Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
    Type: Application
    Filed: June 18, 2020
    Publication date: November 3, 2022
    Inventors: Giovanni Cianchetta, Byron DeLaBarre, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan, Tao Guo, Li Zhang
  • DHFR TUNABLE PROTEIN REGULATION
    Publication number: 20220213449
    Abstract: The present invention is related to compositions and methods for the regulated and controlled expression of proteins.
    Type: Application
    Filed: December 28, 2021
    Publication date: July 7, 2022
    Applicant: Obsidian Therapeutics, Inc.
    Inventors: Vipin SURI, Dan Jun LI, Dexue SUN, Byron DELABARRE, Vijaya BALAKRISHNAN, Brian DOLINSKI, Mara Christine INNISS, Grace Y. OLINGER
  • PDE5 compositions and methods for immunotherapy
    Patent number: 11241485
    Abstract: The present invention relates to compositions and methods for the regulated and controlled expression of proteins. Methods for inducing anti-cancer immune responses in a subject are also provided.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: February 8, 2022
    Assignee: OBSIDIAN THERAPEUTICS, INC.
    Inventors: Vipin Suri, Byron Delabarre, Michael N. Gladstone, Celeste Richardson, Brian Dolinski, Abhishek Kulkarni, Mara Christine Inniss, Dexue Sun, Dan Jun Li, Grace Y. Olinger, Scott Francis Heller
  • Bi-Specific Fusion Proteins
    Publication number: 20210214463
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Application
    Filed: March 25, 2021
    Publication date: July 15, 2021
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-specific fusion proteins
    Patent number: 10988547
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: April 27, 2021
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
  • Bi-Specific Fusion Proteins
    Publication number: 20210040233
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 11, 2021
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre
  • Bi-specific fusion proteins
    Patent number: 10858450
    Abstract: Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: December 8, 2020
    Assignee: Silver Creek Pharmaceuticals, Inc.
    Inventors: Ulrik Bjerl Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre